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Abstract
Background and aim Epstein-Barr virus (EBV) is a proposed trigger in the etiopathogenesis of inflammatory bowel disease
(IBD) and is associated with lymphoproliferative diseases. Nevertheless, testing for EBV DNA in the intestinal mucosa and
screening for EBV infection before initiation of a drug therapy are not routinely performed. The aim of this article is to increase
awareness of the relevance of EBV infection in specific clinical situations.
Methods In this short communication, we describe the disease course of three IBD patients with EBV infection, varying from
EBV reactivation during disease flare up to a trigger of EBV-related mucocutaneous ulcer (EBV-MCU) and haemophagocytic
lymphohistiocytosis (HLH).
Results Our first patient was diagnosed with EBV reactivation-associated severe colitis and showed a rapid clinical improvement
after induction therapy with infliximab and azathioprine. Without antiviral treatment, the patient remained in complete remission
and no complications of EBVwere seen. After diagnosing EBV-MCU in the second patient, immunosuppressive medication was
discontinued and four infusions of rituximab resulted in a rapid clinical recovery and eventually complete response. After
discontinuation of the immunosuppression in our last patient with haemophagocytic lymphohistiocytosis, treatment with a
combination of corticosteroid and antiviral therapy resulted in a complete recovery over a time span of several weeks.
Conclusion EBV infection has a wide variety of potentially life-threatening clinical manifestations in IBD patients. Testing for
EBV in case of a flare up and screening for EBV before the start of immunosuppressive therapy will create awareness for EBV-
related symptoms or complications during follow-up.
Keywords Inflammatory bowel disease . Epstein Barr-virus . Haemophagocytic lymphohistiocytosis . EBV-associated
mucocutaneous ulcer
Introduction
Epstein-Barr virus (EBV) has been proposed as a trigger in the
complex multifactorial etiopathogenesis of inflammatory
bowel disease (IBD) [1], as well as an aggravating agent dur-
ing flares and for perpetuation of the inflammatory process.
[2] In addition, EBV-associated lymphoproliferative disease
in IBD is a feared complication, mostly attributed to immuno-
suppressive agents. [3] Nevertheless, indications for testing
the presence of EBV in intestinal mucosa of IBD patients are
unclear and serologic EBV screening before initiation of drug
therapy is not routinely performed. To increase awareness of
its relevance, we describe the disease course of three IBD
patients with an EBV infection.
Case 1
A 29-year-old male patient with ulcerative proctitis, Montreal
classification E1S2, in complete remission for 4 years, pre-
sented with a 4-week history of bloody diarrhoea, low-grade
fever and weight loss. Physical examination was unremark-
able. Blood results showed CRP (C-reactive protein) 109 (<
10) mg/L, haemoglobin (Hb) 6.6 (8.6–10.5) mmol/L and
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white blood cell count (WBC) 12.1 (3.5–10) × 109/L. Renal
function and liver tests were normal. Sigmoidoscopy revealed
a diffuse, erythematous, thickened mucosa with erosions and
fibrin. Scattered throughout the mucosa, there were numerous
typical small cavities, measuring 2 to 5 mm (Fig. 1a).
Pathology examination demonstrated chronic active inflam-
mation with ulceration, cryptitis, crypt abscesses and several
EBV-encoded RNA (EBER)-positive lymphocytes (non-
blasts) (Fig. 1b). Polymerase chain reaction (PCR) on biopsy
specimens tested positive for EBVand negative for HSV1 and
HSV2 and CMV. Serology was positive for immunoglobulin
G (IgG) EBV viral capsid antigen (VCA), Epstein-Barr
nucleid acid (EBNA) and early antigen (EA) antibodies and
negative for immunoglobulin M (IgM) EBV VCA. A severe
exacerbation of ulcerative colitis complicated by reactivation
of EBV was diagnosed. Patient started induction therapy with
infliximab and azathioprine and showed a rapid clinical im-
provement. No complications of EBV were seen, and patient
remained in long-term clinical, biochemical and endoscopic
remission.
Case 2
A 34-year-old male patient with ulcerative colitis, Montreal
classification E2S2, with long-term clinical remission with
mesalamine and 6-mercaptopurine (6-MP) presented with ab-
dominal pain, night sweats haematochezia and severe anal
pain. Sigmoidoscopy revealed a deep ulcer measuring 15 ×
20 mm in the descending colon, several smaller ulcers in the
sigmoid colon and a large circumferential rectal ulcer measur-
ing 10 cm, localised above the anal ring (Fig. 1c). Colon
biopsies showed a large area of chronic active, necrotic
ulceration with a polymorphous infiltrate of lymphocytes
and medium- and large-sized immunoblasts. The
immunoblasts were especially EBV-encoded RNA (EBER)
immunohistochemistry positive (Fig. 1d). Clonality was prov-
en with immunoglobulin gene rearrangement analysis. Blood
tests showed CRP 43 (< 10) mg/L, Hb 7.4 (8.6–10.5) mmol/L,
WBC 4.6 (3.5–10) × 109/L and lactate dehydrogenase (LDH)
153 (< 248) U/L. Renal and liver function were unremarkable.
PCR for EBV-DNA on the biopsies was positive.
As EBV-related mucocutaneous ulcer (EBV-MCU) and
diffuse large B cell lymphoma were considered, 6-MP was
stopped, patient was referred to the haematologist and a pos-
itron emission tomography (PET) scan was performed. The
PET scan showed only local FDG avidity in the descending
colon and rectum with two enlarged perirectal lymph nodes.
EBV-MCU was the most likely diagnosis. After 4 weeks, the
ulcer slightly decreased in size, but colonic biopsies showed
persistent necrotic ulcerat ion with EBV-posit ive
immunoblasts. Treatment with four infusions of rituximab
was prescribed and a rapid clinical recovery occurred.
During 1-year follow-up, gradual improvement of the ulcer
was seen, without signs of lymphoma in the colon biopsies.
Patient remained in clinical remission with mesalamine
monotherapy.
Case 3
A 17-year-old female patient, presented with a 2-week
history of fever, night sweats and painless cervical
lymphadenopathy. She had been treated with azathio-
prine for 1 year for Crohn’s disease (CD), Montreal
classification A1L1B1. EBV status was unknown prior
Fig. 1 a Punched-out ulcers as
endoscopic findings of EBV-
associated colitis in active ulcera-
tive colitis, associated with reac-
tivation of EBV infection. b
Diffuse severe chronic and active
inflammation, cryptitis and crypt
abscesses. Few EBER-positive
lymphocytes in the lamina propria
in the colon-epithelium (EBER ×
200). cDeep punched-out ulcer of
15 × 20 mm in the descending
colon. d Chronic active ulcerative
inflammation with EBV-positive
immunoblasts (EBER, × 200)
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to presentation. At physical examination, an enlarged
submandibular lymph node was noted. Blood tests
showed CRP 45 (< 10) mg/L, Hb 5.6 (7.5–9.5)
mmol/L, WBC 1.6 (3.5–10) × 109/L (lymphocytes 24.2%
neutrophils 1.17 (1.5–7.5) × 109/L), bilirubin 109 (0–16)
μmol/L, ALAT 193 (< 34) U/L, ferritin 1798 (10–140)
μg/L, fibrinogen 3.5 (1.5–3.6) g/L, triglycerides 1.58 (0.4–
1.6) mmol/L and soluble IL-2 receptor 67,200 (0–2500) pg/
mL. A primary EBV infection was concluded after measuring
high levels of EBV IgM antibodies and EBV viral load of
112.000 IU/mL using PCR. Computed tomography (CT) scan
showed diffuse lymphadenopathy and hepatosplenomegaly.
Lymph node aspiration showed architectural distortion with
small T cell and B cell lymphocytes, some of which are EBER
positive, compatible with a primary EBV infection. Bone mar-
row aspirate revealed increased numbers of macrophages and
haemophagocytosis, after which haemophagocytic
lymphohistiocytosis (HLH) was diagnosed. Treatment with
azathioprine was stopped and oral dexamethasone and acyclo-
vir were started. Shortly thereafter, a rapid fall of the EBV
viral load was measured. Ferritin rose to a maximum of
4978 μg/L and total bilirubin and ALAT to a maximum of
201 μmol/L and 768 U/L, respectively. Acyclovir was
discontinued after 10 days; dexamethasone was tapered in
30 days.
Three months later, the EBV viral load had decreased to a
minimal value and hepatosplenomegaly had disappeared.
Without immunosuppressive medication, she remained in
long-term remission.
Discussion
These cases illustrate the spectrum of clinical and endoscopic
complications of EBV infection in IBD patients. Several stud-
ies have reported on the presence of EBV in the intestinal
mucosa of IBD patients with active inflammation and ob-
served prevalences are as high as 64% using PCR assays of
the EBV genome in inflamed colonic mucosa. [1, 4] However,
it remains unclear whether the virus is involved in the patho-
genesis or is an innocent bystander. The first case of this series
is in line with previous observations that presence of EBV in
inflamed colonic mucosa and increased proliferation are asso-
ciated with severe mucosal inflammation. [5] Active inflam-
mation with intramucosal expansion of EBV-infected B-lym-
phocytes might cause local impairment of viral immunity and
subsequently self-perpetuation of the disease process. [2, 5]
Mucosal immunity may be impaired because of the IBD itself,
or may result from immunosuppressive medication. The im-
munomodulatory effects of EBV could delay the resolution of
the IBD-associated inflammation, thus contributing to disease
progression.
The colonic mucosal cavities seen in case 1 are sim-
ilar to the punched-out ulcers that have been described
in CMV-associated colitis. [6] To our knowledge, this is
the first case in which this type of endoscopic findings
is attributed to an associated solitary EBV infection. In
CMV-associated colitis, antiviral treatment has the po-
tential to shorten duration of severe exacerbations. [7]
Although our patient responded rapidly to immunosup-
pressive therapy only, antiviral treatment may be valu-
able in patients with refractory disease showing signs of
EBV-related disease. [8]
EBV-positive mucocutaneous ulcer (EBV-MCU), as
described in case 2, is a rare B cell lymphoproliferative
disorder that can affect the oropharynx, gastrointestinal
tract and skin. [9] Main risk factors for the development
of EBV-MCU are immunosuppression and age-related
immunosenescence. [9] Principle treatment consists of
cessation of immunosuppressive medication; however,
in some patients, more intensive therapy is necessary.
[9] Lymphoproliferative disorders occur more often in
IBD, particularly in patients on thiopurines, and are fre-
quently associated with EBV infection. [3] Thiopurines
may be responsible for decreased immunosurveillance of
EBV-infected B cells. Since the absolute lymphoma risk
is still very low, it remains unclear whether this associ-
ation justifies restrictive use of thiopurines for IBD. [3]
The European Crohn’s and Colitis Organisation guideline
recommends to consider screening for EBV infection before
initiation of thiopurines. [7] Consideration implies this is not
routinely performed in clinical practice. Case 3 illustrates a
rare complication of an EBV infection in a young IBD patient
treated with azathioprine. HLH is a potentially fatal lympho-
proliferat ive disorder in which macrophages are
overstimulated resulting in phagocytosis of all bone marrow-
derived cells. [10] Although a primary EBV infection is con-
sidered the main initiator of this severe complication, other
infections have been identified as triggers too. [11]
Screening for EBV before start of thiopurines can identify
high-risk individuals and lead to more restrictive use of
thiopurines or more intensive surveillance. However, since
the vast majority of adults will be seropositive and thiopurines
remain a valuable option also in a negative serostatus, screen-
ing strategies are an issue of debate. [12]
In conclusion, EBV infection is associated with a variety of
clinical manifestations in IBD patients, which is illustrated
albeit not restricted to the described cases in this manuscript.
Awareness of EBV infection in IBD patients should be in-
creased, and biopsies should be assessed for the presence of
EBV in patients with specific endoscopic findings of mucosal
cavities, ulcerative tumours or large ulcerative punched-out
lesions. In addition, screening for EBV infection prior to ini-
tiation of immunosuppressive medication may be useful to
create alertness for EBV-related complications during
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follow-up, and to carefully weigh the risks and benefits of the
immunosuppressive treatment, especially in children and
adolescents.
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